In the News May 22, 2017

The Pink Sheet | US FDA Urged To Rethink Warning Letters To Avoid 'Collateral Damage'

Cathy Burgess is quoted about the impact that warning letters from the U.S. Food and Drug Administration can have on a manufacturer's operations and reputation.
Media Contact
Nicholas Clarke
Senior Communications Manager
Phone: 212.210.1222
This website uses cookies to improve functionality and performance. By continuing to browse this site, you are consenting to the use of cookies on this website. For details, see our Privacy Statement